Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 180 participants.

Also called NCT05331144

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05331144
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05331144. Randomized; single masking; primary purpose prevention. Start 2022-10-25 (actual); primary completion 2028-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
Acronym
IPAT
Condition
Cognitively Normal Older Adults
Condition
Hypertension
Condition
Subjective Cognitive Decline
Condition
Family History of Dementia
Intervention (Drug)
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
Intervention (Other)
PCP
Lead sponsor
Rong Zhang (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)
Collaborator
Texas Health Resources (class: other)
Collaborator
Michigan State University (class: other)

Record details

Record id
cardio:ct-nct05331144
Content hash
91ebd4c5120ac94ff77612efbb3a228f0617356f572f7a840f8353fa7fb23b1d